Related Experiment Videos
[Sensitivity of human melanoma xenografts to nitrosoalkylurea antineoplastic agents]
L A Ostrovskaia1, N M Ul'ianova, M M Fomina
1Emanuel' Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia.
Abstract:
We studied the sensitivity of human melanoma (Bro strain) xenografts to drugs of the nitrosoalkylurea (NAU) class: nitrosomethylurea (NMM), karmustin (BCNU), nimustin (ACNU), nitrulin, and ADEKO. High antitumor activity of NAM was shown when the drugs were applied not only at the early, but also at the late stages of tumor progression (tumor mass 400 and 1200 mg, respectively). The therapeutic effect of the drugs was estimated with the use of criteria characterizing the kinetics of tumor regression, increased life span, and survival of treated animals. After early administration of the drugs (Day 4 after tumor transplantation), 67% and 50% of animals survive under the influence of nitrulin and ACNU, respectively, while the rate of tumor regression increased in the sequence nitrulin < karmustin < NMM < ACNU. After late administration (11 days after tumor transplantation), NMM was most effective at increasing survival (35% of survived animals by 35 days of observation), while the rate of tumor regression increased in the sequence ADEKO < NMM < karmustin < nitrulin < ACNU.
Insights
Nitrosoalkylureas (NAUs) show significant antitumor activity against melanoma xenografts, even at late stages. Nimustin (ACNU) and nitrosomethylurea (NMM) demonstrated notable efficacy in prolonging survival and regressing tumors.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Context:
- Human melanoma (Bro strain) xenografts were utilized to assess drug efficacy.
- The study focused on the nitrosoalkylurea (NAU) class of chemotherapeutic agents.
- Drug sensitivity was evaluated at both early and late stages of tumor progression.
Purpose:
- To investigate the antitumor activity of various nitrosoalkylurea (NAU) drugs against melanoma xenografts.
- To compare the efficacy of nitrosomethylurea (NMM), karmustin (BCNU), nimustin (ACNU), nitrulin, and ADEKO.
- To determine the therapeutic effect based on tumor regression, lifespan extension, and animal survival rates.
Summary:
- High antitumor activity was observed with NAU drugs, including nitrosomethylurea (NMM), karmustin (BCNU), nimustin (ACNU), nitrulin, and ADEKO, even in advanced melanoma xenografts.
- Early drug administration (Day 4) resulted in significant survival rates with nitrulin (67%) and ACNU (50%), with tumor regression order: nitrulin < karmustin < NMM < ACNU.
- Late drug administration (Day 11) showed NMM as most effective for survival (35% by Day 35), with tumor regression order: ADEKO < NMM < karmustin < nitrulin < ACNU.
Impact:
- This research highlights the potential of NAU drugs, particularly NMM and ACNU, as effective treatments for melanoma, even when administered at later disease stages.
- The findings provide valuable data for optimizing chemotherapy regimens in melanoma treatment, considering tumor progression.
- The study contributes to understanding drug kinetics and survival benefits offered by different NAU agents in preclinical melanoma models.